Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712033 | 1.00 | POLB (0.52) | POLBEPHX2MAPTMEN1KMT2A | |
| SCHEMBL22746023 | 0.83 | POLB (0.52) | POLBEPHX2MAPTMEN1KMT2A | |
| SCHEMBL10503809 | 0.82 | MAPT (0.49) | EPHX2MAPTMEN1KMT2ALMNA | |
| SCHEMBL3952978 | 0.82 | MAPT (0.49) | EPHX2MAPTMEN1KMT2ALMNA | |
| SCHEMBL3952982 | 0.82 | MAPT (0.49) | EPHX2MAPTMEN1KMT2ALMNA | |
| SCHEMBL30604261 | 0.82 | MAPT (0.43) | POLBEPHX2MAPTMEN1KMT2A | |
| SCHEMBL16073129 | 0.82 | MAPT (0.43) | POLBEPHX2MAPTMEN1KMT2A | |
| SCHEMBL2549288 | 0.81 | MEN1 (0.53) | POLBEPHX2MAPTMEN1KMT2A | |
| SCHEMBL15248883 | 0.79 | CA12 (0.53) | EPHX2MAPTMEN1KMT2ALMNA | |
| SCHEMBL5606769 | 0.79 | CA12 (0.53) | EPHX2MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527841-B2 | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2873669-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | POLB 2802/4885EPHX2 597/4885MAPT 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.